MSB 2.26% 90.5¢ mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-1007

  1. 5,717 Posts.
    lightbulb Created with Sketch. 2058
    Hey, does anyone remember that randomised, doubleblind trial with a couple of hundred Covid ARDS patients, where half of them got doses of Remestemcel to match the dosing used with GVHD?

    Wonder if they had any assay data from that trial that they were able to share with FDA in relation to the GVHD application.

    Just thinking out loud.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
90.5¢
Change
0.020(2.26%)
Mkt cap ! $1.033B
Open High Low Value Volume
88.5¢ 95.0¢ 88.0¢ $5.610M 6.115M

Buyers (Bids)

No. Vol. Price($)
12 317774 90.0¢
 

Sellers (Offers)

Price($) Vol. No.
91.5¢ 23500 2
View Market Depth
Last trade - 16.10pm 06/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.